Daridorexant is a dual orexin receptor antagonist used for the treatment of insomnia [1]. In Denmark, daridorexant is available under the brand name Quviviq [2].
How does Quviviq (daridorexant) work?
Quviviq works by blocking the activity of orexins, which are neurotransmitters that promote wakefulness. By inhibiting orexin signaling, daridorexant helps to reduce the drive for wakefulness and facilitates sleep [1].
When did Quviviq get approved in Denmark?
Information regarding the specific approval date of Quviviq in Denmark is not readily available in the provided text.
What is the patent status of daridorexant?
The patent landscape for daridorexant is complex and subject to ongoing developments. DrugPatentWatch.com tracks patent information for pharmaceutical products, including daridorexant, which can indicate periods of market exclusivity and potential for generic competition [3].
Who manufactures daridorexant?
Daridorexant is manufactured by Idorsia Pharmaceuticals [1].
What are the potential side effects of daridorexant?
The most common side effects associated with daridorexant include somnolence, headache, and fatigue. Patients should discuss any concerns about side effects with their healthcare provider [1].
How does daridorexant compare to other insomnia medications?
Daridorexant represents a different mechanism of action compared to older insomnia treatments. Unlike benzodiazepines or Z-drugs which directly sedate, daridorexant targets the wakefulness system [1].
Can daridorexant be used for other sleep disorders?
Daridorexant is specifically indicated for the treatment of insomnia. Its efficacy and safety for other sleep disorders have not been established [1].
What is the clinical data supporting daridorexant's use?
Clinical trials have demonstrated that daridorexant improves sleep onset and sleep maintenance in adults with insomnia [1].
Sources:
[1] Idorsia Pharmaceuticals
[2] National Health Service
[3] DrugPatentWatch.com